Company intelligence / Profile preview

Syntese

Ownership: Private
Development stage: Other

Overview

Syntese is a world-leading manufacturer of mesalazine (5-aminosalicylic acid), an active pharmaceutical ingredient used in the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. With over 40 years’ experience and extensive regulatory compliance expertise, it supplies high-quality APIs globally for commercial use

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Syntese.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntese.

Explore the full profile